Article and Video CATEGORIES
The last portion of Dr. Leighl's program on "Highlights of Lung Cancer from 2012" covered maintenance therapy, specifically focusing on the latest report of results from the PARAMOUNT trial, which demonstrated a significant survival benefit for maintenance Alimta (pemetrexed) continued after four cycles of the first line combination of cisplatin and Alimta. What does this mean? Here's Dr. Leighl's summary of the trial and her discussion of its implications.
[powerpress]
Dr. Leighl Highlights in LC 2012 Pt 5 Maint Rx Audio Podcast
Dr. Leighl Highlights in LC 2012 Pt 5 Maint Rx Figs
This was the last of the highlights she covered, so we'll move to another webinar soon.
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Thank you so much for the response! I have seen a lot of your post on here and it's really awesome of you to take the time to reply to all...
ONKTALK is tomorrow.
I hope to see you there.
The forum is now available on demand here. Don't hesitate to ask questions as they come up.
Take care,
Janine
Hi happybluesun, Welcome to Grace. I'm sorry your mom is going through this.
Driver mutations are mutations that drive (or cause) the cancer. Having more than one driver mutation is...
Hi, I'm sorry you're having these issues. The type of shoulder pain that feels like nerve pain is most likely nerve pain. The type of tumor that causes similar shoulder pain...